Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 349 of 1,261
  1. US 10988782

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  2. US 10988768

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  3. AU 2019328599

    Compounds and methods for treating fungal infections

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Apr 22, 2021 · Expires Apr 17, 2041

    granted
  4. EP 3807293

    PEPTIDE MIT HEMMENDER WIRKUNG AUF NEURONALE EXOZYTOSE

    ACRAF [IT] · Granted Apr 21, 2021 · Expires Apr 16, 2041

    granted
  5. EP 3807294

    PEPTIDE MIT HEMMENDER WIRKUNG AUF MUSKARINREZEPTOR M3

    ACRAF [IT] · Granted Apr 21, 2021 · Expires Apr 16, 2041

    granted
  6. US 10980746

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Vertex Pharmaceuticals Incorporated · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  7. US 10980780

    Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases

    NEUROSENSE THERAPEUTICS LTD. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  8. US 10980825

    Cyclic dinucleotide

    Takeda Pharmaceutical Company Limited · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  9. US 10982203

    Modified factor IX polypeptides and uses thereof

    Catalyst Biosciences, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  10. US 10981855

    Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

    PTC THERAPEUTICS, INC. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  11. US 10982212

    Conserved HBV and HCV sequences useful for gene silencing

    Alnylam Pharmaceuticals, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  12. US 10983128

    CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

    Providence Health & Services · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  13. US 10980841

    Methods and compositions for in vivo induction of pancreatic beta cell formation

    The Board of Regents of the University of Texas System · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  14. US 10980861

    Glucokinase activator compositions for the treatment of diabetes

    VTV THERAPEUTICS LLC · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  15. US 10980889

    C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  16. US 10982231

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  17. US 10981906

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Aclaris Therapeutics, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  18. US 10981915

    Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors

    Valo Early Discovery, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  19. US 10980755

    LRH-1 modulators

    The Regents of the University of California · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  20. US 10981951

    Therapeutics for the treatment of glaucoma

    Regents of the University of Minnesota · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  21. US 10981896

    Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase

    The Board of Regents of the University of Texas System · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  22. US 10982215

    Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  23. US 10982221

    Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  24. US 10982230

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.